3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Multiple Myeloma
20
Leukemia, Myeloid, Acute
8
Recurrence
7
Neoplasms, Plasma Cell
4
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma
3
Thymoma
2
Ovarian Neoplasms
2
Carcinoma
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Richter's Transformation
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Melanoma
1
MDS
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Cisplatin
39
Radiotherapy
21
Carboplatin
21
Cetuximab
20
Paclitaxel
19
Docetaxel
17
Radiotherapy, Intensity-Modulated
15
pembrolizumab
14
Fluorouracil
13
Drug Therapy
10
Nivolumab
8
Radiation
6
cemiplimab
5
atezolizumab
5
Panitumumab
5
Oxaliplatin
5
Erlotinib Hydrochloride
5
Chemoradiotherapy
5
Afatinib
5
Surgical Procedures, Operative
4
durvalumab
3
Surveys and Questionnaires
3
Methotrexate
3
Leucovorin
3
Lapatinib
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
palbociclib
2
osimertinib
2
dacomitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Squamous Cell
×
selinexor
×
Clear all
NCT02213133
2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2
Terminated
45 enrolled
12 charts